KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Efficacy of Lumateperone in depression associated with bipolar II disorder: a pooled analysis of late-phase clinical trials.

Suresh Durgam, Hassan Lakkis, Susan G Kozauer, Changzheng Chen, Roger S McIntyre

CNS Spectr 30(1) e80

PMID41017591
PMCIDPMC13064759
DOI10.1017/S1092852925100564
发表日期2025-09-29
摘要

摘要

OBJECTIVE: Treatment options are limited for depressive episodes in patients with bipolar II disorder. This post hoc analysis evaluated the efficacy of lumateperone in three pooled short-term, Phase 3 studies in patients with a major depressive episode (MDE) associated with bipolar II disorder. METHODS: This post hoc analysis pooled data from patients (18-75 years) with DSM-5 diagnosed bipolar II disorder experiencing an MDE in randomized, double-blind, placebo-controlled studies of lumateperone 42 mg monotherapy (Study 401, Study 404) and adjunctive therapy to lithium or valproate (Study 402). Primary and key secondary outcomes were change from baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) Total and Clinical Global Impression Scale-Bipolar Version-Severity (CGI-BP-S) scores. Safety was also assessed. RESULTS: Lumateperone significantly improved MADRS Total score at Day 43 in the bipolar II population (placebo, n = 87; lumateperone, n = 87; least squares mean difference vs. placebo [LSMD], -4.0; P < .05). In the bipolar II population, lumateperone significantly improved CGI-BP-S Total (LSMD, -1.0; P < .05), Depression (LSMD, -0.5; P < .05), and Overall Bipolar Illness scores (LSMD, -0.5; P < .05) compared with placebo at Day 43. No new safety signals were identified, with minimal risk of extrapyramidal symptoms, cardiometabolic abnormalities, or prolactin elevation. CONCLUSIONS: Lumateperone 42 mg monotherapy or adjunctive therapy significantly improved symptoms of depression and disease severity in patients with bipolar II disorder across Phase 3 studies. Lumateperone was generally well tolerated. These results support lumateperone 42 mg to treat MDEs associated with bipolar II disorder.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。